Inclusion Criteria:

- Age 18-80 years

- Histologically confirmed (according to the WHO classification) diffuse large B-cell
lymphoma stage II-IV

- No previous treatment for lymphoma. Corticosteroids for alleviation of lymphoma
associated symptoms are allowed

- WHO performance status 0-2

- HIV negativity

- Seronegativity for HCV, HBsAg, anti-HBc, or other active infection uncontrolled by
treatment

- Absence of psychiatric illness or condition which could interfere with the subjects
ability understand the requirements of the study

- Absence of neurological or neuropsychiatric disorder, interfering with the
requirements of the study

- Absence of hearing impairment > grade 2

- Absence of porphyria

- In females: absence of pregnancy and lactation

- All subjects must agree to abstain from donating blood while taking study drug
therapy and for one week following discontinuation of study drug therapy

- All subjects must agree not to share study medication with another person, and to
return all unused study drug to investigators

- Written informed concent according to ICH/GCP and Swedish regulations